Featured Research

from universities, journals, and other organizations

Novel Drug Shows Potential For Treating Leukemia

Date:
April 21, 2007
Source:
University of Texas M. D. Anderson Cancer Center
Summary:
Researchers have found that a novel targeted therapy effectively treats acute leukemia in animal models by preventing cancer cells from being purged of damaged proteins.

Researchers from the Children's Cancer Hospital at The University of Texas M. D. Anderson Cancer Center have found that a novel targeted therapy effectively treats acute leukemia in animal models by preventing cancer cells from being purged of damaged proteins.

In the March online issue of the journal Blood, investigators reported that the new proteasome inhibitor, NPI-0052, not only successfully kills leukemia cells, but also shows greater efficacy than its predecessor bortezomib when combined with other agents in animal models.

According to researchers, proteasomes clean out mutated or damaged proteins within cells, which promotes cell growth and allows cancer cells to rapidly reproduce. Proteasome inhibitors block this process, resulting in apoptosis, or cell death, of the malignant cells.

Bortezomib is the first and only FDA-approved proteasome inhibitor. Although it is effective for treating multiple myeloma and mantle cell lymphoma, it was proven to be ineffective as a single agent against leukemia in clinical trials. NPI-0052 varies from bortezomib in ways that researchers at M. D. Anderson hope will make NPI-0052 effective in a human clinical trial.

"NPI-0052 targets the proteasome through different intermediaries and is more potent than bortezomib in leukemia cells," says senior author Joya Chandra, Ph.D., assistant professor of pediatrics from the Children's Cancer Hospital at M. D. Anderson. "Therefore we can use less of the drug to inhibit the proteasome."

NPI-0052 inhibits the main enzymatic activity of the proteasome three times more effectively than bortezomib as a single agent. When combined with a histone deacetylase (HDAC) inhibitor, another anti-cancer agent, NPI-0052 achieves four-fold greater synergistic effects than bortezomib.

M. D. Anderson currently has a Phase I clinical trial led by principal investigator Razelle Kurzrock, M.D., to test NPI-0052 on adult patients with solid tumor malignancies and recurrent lymphoma. Chandra's group is the first group to be studying the effects of the drug in acute leukemia models.

"This drug, so far, has shown efficacy in animal models of leukemia, myeloma and colon cancer, and it has worked to kill multiple myeloma cells resistant to bortezomib," says Chandra. "As a result of our research, we're looking at the feasibility of combining NPI-0052 with HDAC inhibitors in the future to treat leukemia."

Chandra's lab has received funding from the National Cancer Institute Leukemia SPORE grant awarded to M. D. Anderson and from an NCI training grant to graduate student, Claudia Miller.

Co-authors on the project are first author Claudia Miller, Kechen Ban, Ph.D., and Melanie Dujka from the Department of Pediatrics Research; David McConkey, Ph.D., from the Department of Cancer Biology; Mark Munsell from the Division of Quantitative Sciences, all at M. D. Anderson Cancer Center; and Michael Palladino, Ph.D., from Nereus Pharmaceuticals.


Story Source:

The above story is based on materials provided by University of Texas M. D. Anderson Cancer Center. Note: Materials may be edited for content and length.


Cite This Page:

University of Texas M. D. Anderson Cancer Center. "Novel Drug Shows Potential For Treating Leukemia." ScienceDaily. ScienceDaily, 21 April 2007. <www.sciencedaily.com/releases/2007/04/070419155119.htm>.
University of Texas M. D. Anderson Cancer Center. (2007, April 21). Novel Drug Shows Potential For Treating Leukemia. ScienceDaily. Retrieved April 25, 2014 from www.sciencedaily.com/releases/2007/04/070419155119.htm
University of Texas M. D. Anderson Cancer Center. "Novel Drug Shows Potential For Treating Leukemia." ScienceDaily. www.sciencedaily.com/releases/2007/04/070419155119.htm (accessed April 25, 2014).

Share This



More Health & Medicine News

Friday, April 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Deadly Fungus Killing Bats, Spreading in US

Deadly Fungus Killing Bats, Spreading in US

AP (Apr. 24, 2014) A disease that has killed more than six million cave-dwelling bats in the United States is on the move and wildlife biologists are worried. White Nose Syndrome, discovered in New York in 2006, has now spread to 25 states. (April 24) Video provided by AP
Powered by NewsLook.com
Companies Ramp Up Wellness to Lower Health Costs

Companies Ramp Up Wellness to Lower Health Costs

AP (Apr. 24, 2014) That little voice telling you to exercise, get in shape and get healthy is probably coming from your boss. More companies are beefing up wellness programs to try and cut down their health care costs. (April 24) Video provided by AP
Powered by NewsLook.com
Blood From World's Oldest Woman Suggests Life Limit

Blood From World's Oldest Woman Suggests Life Limit

Newsy (Apr. 24, 2014) Scientists say for the extremely elderly, their stem cells might reach a state of exhaustion. This could limit one's life span. Video provided by Newsy
Powered by NewsLook.com
FDA Wants To Ban Sales Of E-Cigarettes To Minors

FDA Wants To Ban Sales Of E-Cigarettes To Minors

Newsy (Apr. 24, 2014) The Food and Drug Administration wants to crack down on the use of e-cigarettes, banning the sale of the product to minors. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins